AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
March 12 2021 - 8:00AM
Business Wire
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company developing therapeutics for human aging and
regeneration, announced today the online publication of data
relating to regeneration, aging, and cancer in bioRxiv. The paper
titled “Differential Expression of α, β, and γ Protocadherin
Isoforms During Differentiation, Aging, and Cancer” presents for
the first time data relating to mechanisms cells may use in the
process of regeneration. The paper discloses alterations in certain
genes that may prevent regeneration from occurring in adult humans.
It also provides evidence that the family of genes may be involved
in a wide array of human cancers.
“We believe these results have significant importance for
researchers working not only in the field of aging research, but
the field of cancer research as well,” said Michael D. West, PhD,
CEO of AgeX. “As a result, we published this data as a non-peer
reviewed preprint to accelerate the timeline during which other
scientists can see and test the results in their own laboratories.
We plan to implement the findings in our induced Tissue
Regeneration (iTR) program, and as a result, have filed a series of
relevant patent applications. We plan to publish the results at a
later time in a peer-reviewed format.”
Authors on the paper include: Michael D. West, Ivan Labat, Jie
Li, Pam Sim, Jeffrey Janus, and Hal Sternberg of AgeX; Hayley
Mangelson, Shawn Sullivan, and Ivan Liachko of Phase Genomics,
Inc.; Paul Labhart, Maddy Craske, and Brian Egan of Active Motif,
Inc.; Karen B. Chapman of Eclipse Bioinnovations, Inc.; Nafees N.
Malik of Juvenescence Ltd.; and Dana Larocca of DC Biotechnology.
The article is available for viewing at
https://www.biorxiv.org/content/10.1101/2021.03.07.434314v1.full. A
video explaining the results is available for viewing at
https://vimeo.com/522148118.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly-defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a variety of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan
and is seeking opportunities to establish licensing and
collaboration agreements around its broad IP estate and proprietary
technology platforms.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its subsidiaries
particularly those mentioned in the cautionary statements found in
more detail in the “Risk Factors” section of AgeX’s Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. AgeX specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210312005116/en/
Contact for AgeX: Dr. Nafees Malik Chief Operating
Officer nmalik@agexinc.com
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024